Cargando…
Cytoreductive Surgery plus Hyperthermic Intraperitoneal Chemotherapy to Treat Advanced/Recurrent Epithelial Ovarian Cancer: Results from a Retrospective Study on Prospectively Established Database()
BACKGROUND: Despite the best standard treatment, optimal cytoreductive surgery (CRS) and platinum/taxane-based chemotherapy, prognosis of advanced epithelial ovarian carcinoma (EOC) remains poor. Recently, CRS plus hyperthermic intraperitoneal chemotherapy (HIPEC) has been developed to treat periton...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Neoplasia Press
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4833965/ https://www.ncbi.nlm.nih.gov/pubmed/27084429 http://dx.doi.org/10.1016/j.tranon.2016.02.002 |
_version_ | 1782427419870756864 |
---|---|
author | Sun, Jian-Hua Ji, Zhong-He Yu, Yang Wu, Hai-Tao Huang, Chao-Qun Zhang, Qian Yang, Xiao-Jun Yonemura, Yutaka Li, Yan |
author_facet | Sun, Jian-Hua Ji, Zhong-He Yu, Yang Wu, Hai-Tao Huang, Chao-Qun Zhang, Qian Yang, Xiao-Jun Yonemura, Yutaka Li, Yan |
author_sort | Sun, Jian-Hua |
collection | PubMed |
description | BACKGROUND: Despite the best standard treatment, optimal cytoreductive surgery (CRS) and platinum/taxane-based chemotherapy, prognosis of advanced epithelial ovarian carcinoma (EOC) remains poor. Recently, CRS plus hyperthermic intraperitoneal chemotherapy (HIPEC) has been developed to treat peritoneal carcinomatosis (PC). This study was to evaluate the efficacy and safety of CRS+HIPEC to treat PC from advanced/recurrent EOC. METHODS: Forty-six PC patients from advanced EOC (group A) or recurrent EOC (group B) were treated by 50 CRS+HIPEC procedures. The primary endpoints were progression-free survival (PFS) and overall survival (OS); the secondary endpoints were safety profiles. RESULTS: The median OS was 74.0 months [95% confidence interval (CI) 8.5-139.5] for group A versus 57.5 months (95% CI 29.8-85.2) for group B (P = .68). The median PFS was not reached for group A versus 8.5 months (95% CI 0-17.5) for group B (P = .034). Better median OS correlated with peritoneal cancer index (PCI) < 20 (76.6 months for PCI ≤ 20 group vs 38.5 months for PCI > 20 group, P = .01), complete cyroreduction (residual disease ≤ 2.5 mm) [79.5 months for completeness of cytoreduction (CC) score 0-1 vs 24.3 months for CC 2-3, P = .00], and sensitivity to platinum (65.3 months for platinum-sensitive group vs 20.0 for platinum-resistant group, P = .05). Serious adverse events occurred in five patients (10.0%). Multivariate analysis identified CC score as the only independent factor for better survival. CONCLUSION: For advanced/recurrent EOC, CRS+HIPEC could improve OS with acceptable safety. |
format | Online Article Text |
id | pubmed-4833965 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Neoplasia Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-48339652016-04-27 Cytoreductive Surgery plus Hyperthermic Intraperitoneal Chemotherapy to Treat Advanced/Recurrent Epithelial Ovarian Cancer: Results from a Retrospective Study on Prospectively Established Database() Sun, Jian-Hua Ji, Zhong-He Yu, Yang Wu, Hai-Tao Huang, Chao-Qun Zhang, Qian Yang, Xiao-Jun Yonemura, Yutaka Li, Yan Transl Oncol Original article BACKGROUND: Despite the best standard treatment, optimal cytoreductive surgery (CRS) and platinum/taxane-based chemotherapy, prognosis of advanced epithelial ovarian carcinoma (EOC) remains poor. Recently, CRS plus hyperthermic intraperitoneal chemotherapy (HIPEC) has been developed to treat peritoneal carcinomatosis (PC). This study was to evaluate the efficacy and safety of CRS+HIPEC to treat PC from advanced/recurrent EOC. METHODS: Forty-six PC patients from advanced EOC (group A) or recurrent EOC (group B) were treated by 50 CRS+HIPEC procedures. The primary endpoints were progression-free survival (PFS) and overall survival (OS); the secondary endpoints were safety profiles. RESULTS: The median OS was 74.0 months [95% confidence interval (CI) 8.5-139.5] for group A versus 57.5 months (95% CI 29.8-85.2) for group B (P = .68). The median PFS was not reached for group A versus 8.5 months (95% CI 0-17.5) for group B (P = .034). Better median OS correlated with peritoneal cancer index (PCI) < 20 (76.6 months for PCI ≤ 20 group vs 38.5 months for PCI > 20 group, P = .01), complete cyroreduction (residual disease ≤ 2.5 mm) [79.5 months for completeness of cytoreduction (CC) score 0-1 vs 24.3 months for CC 2-3, P = .00], and sensitivity to platinum (65.3 months for platinum-sensitive group vs 20.0 for platinum-resistant group, P = .05). Serious adverse events occurred in five patients (10.0%). Multivariate analysis identified CC score as the only independent factor for better survival. CONCLUSION: For advanced/recurrent EOC, CRS+HIPEC could improve OS with acceptable safety. Neoplasia Press 2016-04-12 /pmc/articles/PMC4833965/ /pubmed/27084429 http://dx.doi.org/10.1016/j.tranon.2016.02.002 Text en © 2015 Pfizer Inc. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Original article Sun, Jian-Hua Ji, Zhong-He Yu, Yang Wu, Hai-Tao Huang, Chao-Qun Zhang, Qian Yang, Xiao-Jun Yonemura, Yutaka Li, Yan Cytoreductive Surgery plus Hyperthermic Intraperitoneal Chemotherapy to Treat Advanced/Recurrent Epithelial Ovarian Cancer: Results from a Retrospective Study on Prospectively Established Database() |
title | Cytoreductive Surgery plus Hyperthermic Intraperitoneal Chemotherapy to Treat Advanced/Recurrent Epithelial Ovarian Cancer: Results from a Retrospective Study on Prospectively Established Database() |
title_full | Cytoreductive Surgery plus Hyperthermic Intraperitoneal Chemotherapy to Treat Advanced/Recurrent Epithelial Ovarian Cancer: Results from a Retrospective Study on Prospectively Established Database() |
title_fullStr | Cytoreductive Surgery plus Hyperthermic Intraperitoneal Chemotherapy to Treat Advanced/Recurrent Epithelial Ovarian Cancer: Results from a Retrospective Study on Prospectively Established Database() |
title_full_unstemmed | Cytoreductive Surgery plus Hyperthermic Intraperitoneal Chemotherapy to Treat Advanced/Recurrent Epithelial Ovarian Cancer: Results from a Retrospective Study on Prospectively Established Database() |
title_short | Cytoreductive Surgery plus Hyperthermic Intraperitoneal Chemotherapy to Treat Advanced/Recurrent Epithelial Ovarian Cancer: Results from a Retrospective Study on Prospectively Established Database() |
title_sort | cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy to treat advanced/recurrent epithelial ovarian cancer: results from a retrospective study on prospectively established database() |
topic | Original article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4833965/ https://www.ncbi.nlm.nih.gov/pubmed/27084429 http://dx.doi.org/10.1016/j.tranon.2016.02.002 |
work_keys_str_mv | AT sunjianhua cytoreductivesurgeryplushyperthermicintraperitonealchemotherapytotreatadvancedrecurrentepithelialovariancancerresultsfromaretrospectivestudyonprospectivelyestablisheddatabase AT jizhonghe cytoreductivesurgeryplushyperthermicintraperitonealchemotherapytotreatadvancedrecurrentepithelialovariancancerresultsfromaretrospectivestudyonprospectivelyestablisheddatabase AT yuyang cytoreductivesurgeryplushyperthermicintraperitonealchemotherapytotreatadvancedrecurrentepithelialovariancancerresultsfromaretrospectivestudyonprospectivelyestablisheddatabase AT wuhaitao cytoreductivesurgeryplushyperthermicintraperitonealchemotherapytotreatadvancedrecurrentepithelialovariancancerresultsfromaretrospectivestudyonprospectivelyestablisheddatabase AT huangchaoqun cytoreductivesurgeryplushyperthermicintraperitonealchemotherapytotreatadvancedrecurrentepithelialovariancancerresultsfromaretrospectivestudyonprospectivelyestablisheddatabase AT zhangqian cytoreductivesurgeryplushyperthermicintraperitonealchemotherapytotreatadvancedrecurrentepithelialovariancancerresultsfromaretrospectivestudyonprospectivelyestablisheddatabase AT yangxiaojun cytoreductivesurgeryplushyperthermicintraperitonealchemotherapytotreatadvancedrecurrentepithelialovariancancerresultsfromaretrospectivestudyonprospectivelyestablisheddatabase AT yonemurayutaka cytoreductivesurgeryplushyperthermicintraperitonealchemotherapytotreatadvancedrecurrentepithelialovariancancerresultsfromaretrospectivestudyonprospectivelyestablisheddatabase AT liyan cytoreductivesurgeryplushyperthermicintraperitonealchemotherapytotreatadvancedrecurrentepithelialovariancancerresultsfromaretrospectivestudyonprospectivelyestablisheddatabase |